Data for: The clinical implication of gamma globulin levels in patients with non-muscle-invasive bladder cancer
收藏官方服务：
资源简介：
Patient database
应用场景：
创建时间：
2021-01-01
相关数据集
Tumor Stemness Score to Estimate Epithelial-to-Mesenchymal Transition (EMT) and Cancer Stem Cells (CSCs) Characterization and to Predict the Prognosis and Immunotherapy Response in Bladder Urothelial Carcinoma. Tumor Stemness Score to Estimate Epithelial-to-Mesenchymal Transition (EMT) and Cancer Stem Cells (CSCs) Characterization and to Predict the Prognosis and Immunotherapy Response in Bladder Urothelial Carcinoma
Background: The relationships between cancer stem cells (CSCs), epithelial-to-mesenchymal transition (EMT), and the tumor microenvironment (TME) in bladder urothelial carcinoma (BLCA) remain unclear.
NIAID Data Ecosystem110
Table_1_Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer.xlsx
Circulating tumor DNA (ctDNA) can be a prognostic biomarker for non-muscle-invasive bladder cancer (NMIBC); however, targeted sequencing has not been performed to detect ctDNA in NMIBC. We applied tar
NIAID Data Ecosystem70
Sample information on the basis of demography, blood cell counts and RNA quality.
Sample information on the basis of demography, blood cell counts and RNA quality.
NIAID Data Ecosystem50
Additional file 6 of Identification of immune-related and autophagy-related genes for the prediction of survival in bladder cancer
Additional file 6: Table S6. Risk score of each sample from the training cohort.
Figshare2022-08-01 更新70
DataSheet_1_N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.xlsx
Both lncRNAs and the N6-methyladenosine (m6A) modification are key regulators of tumorigenesis and innate immunity. However, little is known about the m6A modification of lncRNAs and their clinical an
NIAID Data Ecosystem60
